Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GSK’s latest phase III shingles trial offers hope to stem cell transplant patients

People who have undergone stem cell transplants typically have weaker immune systems, which makes them more susceptible to viruses such as shingles
Shingrix was shown to reduce the risk of getting shingles by almost 70% with just two doses

GlaxoSmithKline plc’s (LON:GSK) latest phase III trial of its Shingrix shingles vaccine has given some hope to stem cell transplant recipients.

Shingles is caused by the same virus that causes chickenpox and typically presents itself as a painful, itchy rash that develops on one side of the body.

READ: GSK’s ViiV Healthcare kicks off enrolment of big phase III HIV trial in Africa

Viral infections like shingles are particularly prevalent in people who have undergone stem cell transplants given their typically weaker immune systems.

Shingrix - which is a two-dose vaccine and costs around US$280 - has been approved in the US and Canada for otherwise healthy over-50s, but GSK thinks it can reduce the risk of getting shingles in other patient populations too.

The ZOE-HSCT phase III study tested the vaccine on adults over the age of 18 who had just undergone autologous haematopoietic stem cell transplant (auHSCT).

It succeeded in its primary objective, demonstrating that Shingrix reduced the chances of getting the virus by 68% in over-18s and by a similar percentage in over-50s.

The vaccine reduced overall complications linked to shingles by almost 78% and no safety issues were detected during the trials.

GSK said it is evaluating these results together with those of other phase III studies in immune-compromised patient populations.

READ: GSK steals a march on rivals as its two drug, one pill HIV treatment gets green light from FDA

"The immune systems of these stem cell transplant recipients is substantially weakened compared to the general older adult populations studied in other Shingrix efficacy trials," Emmanuel Hanon, Senior Vice President and Head of Vaccines R&D for GSK said.

"This puts them at much higher risk for viral diseases like shingles and, at the same time, makes developing an effective vaccine to help protect them more challenging."

"Today's results, demonstrating the vaccine's ability to help prevent shingles and its complications with just two doses, may provide a much-needed benefit to these patients considering the high incidence and burden of disease they face," he said.

GSK shares were down 0.5% to £12.72 early on Wednesday.

View full GSK profile View Profile

GlaxoSmithKline plc Timeline

Related Articles

Respiratory syncytial virus causes the common cold, for which there is no effective cure.
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use